HBM Biopharma Summit 2026

27th - 29th September 2026

Park Hyatt Zurich
Registration

WELCOME

For more than a decade, HBM hosted yearly summits, providing a meeting platform for industry professionals and investors to exchange views with experts and peers about the latest developments in the biopharma industry. After the highly successful HBM Biopharma Summit 2025 we are delighted to announce the dates for the


HBM BIOPHARMA SUMMIT 2026


DATE & PLACE

27th - 29th September 2026

Park Hyatt Hotel Zurich, Switzerland


SPEAKERS

Jeffrey Berkowitz, Real Endpoints | Meenakshi Datta, Sidley Austin | Richard Girling, Centerview Partners |Mathai Mammen, Parabilis Medicines | Mark C. McKenna, Mirador Therapeutics | Moncef Slaoui, Curevo Vaccine | Stephen J. Ubl, PhRMA

PARTICIPANTS

List of participants PDF download


PRESENTING COMPANIES

Adarx | Alumis | ALX | Biohaven | CellCentric | Coherus Oncology | Corxel | Cstone Pharmaceuticals | Denali | Dren Bio | Electra | Karius | Monte Rosa Therapeutics | NovaBridge | Numab | Nuvation Bio | Parabilis | Perspective | SOBI | Swixx Biopharma | Travere | Trevi | Vicore Pharma | Zymeworks


NETWORKING

With networking being a key element of this event, we look forward to inspiring discussions and a lively exchange of views among all participants.

ACCOMMODATION

The Park Hyatt hotel offers a limited number of rooms during the conference at a reduced rate. These rooms are likely to sell your soon. Please book your room at the Park Hyatt Conference Booking Site

Other nearby hotels inlcude Hotel Motel 1, Baur au Lac, Hotel Alden Splügenschloss


DRESS CODE

Business casual (casual for dinners) throughout the conference.

CONFERENCE PROGRAM

REGISTRATION & WELCOME DESK

Ballroom Foyer

INFORMAL LUNCH AT PARK HYATT HOTEL

Mezzanine Foyer

UETLIBERG - ZURICH'S VERY OWN MOUNTAIN

At 871 metres (2,858 feet) above sea level, the Uetliberg towers over Zurich's rooftops. The Uetliberg Railway takes us almost to the top, leaving only a seven-minute walk through the forest to reach the summit and the Hotel Uto Kulm. From here, you can enjoy a fascinating 360° view. The hotel's own observation tower is the best viewing point. Enjoy a light apéritif while taking in the magnificent panoramic view of the city, the lake and the Alps.

LINDT CHOCO DELUXE PRIVATE TOUR

During this 90-minute guided tour, you will gain an insight into the production of cocoa and chocolate. You will learn how the Mayan 'cult' drink evolved into a European luxury and ultimately became accessible to all. In addition to the tasting stations in the exhibition and the tasting of creamy melting Lindor creations with a Maître Chocolatier, we are also offered the exclusive opportunity to taste ingredients and preliminary products of chocolate production. Finally, you can explore the world of chocolate in the 500 m² Lindt Chocolate Shop, where you will find the finest Swiss chocolate from Lindt, as well as a variety of sweet gift ideas.

TRANSFER TO DINNER LOCATION

Meet in Lobby

INFORMAL DINNER AT RESTAURANT SEEROSE

Restaurant Seerose

Seestrasse 493
8038 Zürich

GROUP TRANSFERS TO PARK HYATT HOTEL

Speakers

Jeffrey Berkowitz

CEO, Real Endpoints

Jeff Berkowitz is one of the rare executives whose career has spanned most key verticals in the global healthcare supply chain with executive committee and other senior roles at UnitedHealth Group, Walgreens Boots Alliance and Merck. Jeff is currently the CEO of Real Endpoints, a leader in providing insights, support and tools to strengthen access to pharmaceutical and digital health innovation for an evolving healthcare landscape with a concentrated focus on value based arrangements, patient services and market access support for biopharma manufacturers and payors. Jeff is also a Senior Advisor to the private equity firm Permira and serves as Chairman of Valeris, a portfolio company focused on patient support services. Prior to Real Endpoints, Jeff served as an Executive Vice President of UnitedHealth Group/Optum where he led Optum’s London-based International division, as CEO while also driving key strategic initiatives within Optum’s pharmacy benefits management division, OptumRx. Prior to joining UnitedHealth Group/Optum, Jeff was a member of the Executive Committee of the Walgreens Boots Alliance where he served as President of Pharma and Global Market Access. In this role, Berkowitz was responsible for generic and branded procurement, inventory management, relationships with pharmaceutical companies as well as the companies pricing and reimbursement strategies with all payors and payor segments. Jeff also led Walgreens specialty pharmacy business with over $10 billion in revenue and 5,800 employees. Before the formation of the Walgreens Boots Alliance, Jeff served as President of Walgreens Boots Alliance Development GmbH, where he was based in Bern, Switzerland for three years, with responsibility for the creation and development of a new joint venture company overseeing relationships with branded and generic pharmaceutical manufacturers. As the senior-most Walgreens executive residing outside of the U.S., Berkowitz led the global health and wellbeing efforts on the ground overseas. Prior to that, Berkowitz served as Walgreens Senior Vice President, Pharmaceutical Development and Market Access and was responsible for all pharmaceutical procurement, inventory management, managed care sales, network contracting and reimbursement. Before joining Walgreens in 2010, Jeff was senior vice president of global market access for Merck & Company, Inc. where he was accountable for all activity related to access, pricing, payer marketing, health outcomes and health technology assessments worldwide and a member of the Global Human Health and Emerging Markets leadership teams. From 2002 to 2009, Berkowitz held a variety of positions with increasing responsibility in market access, sales and marketing with Schering-Plough prior to its acquisition by Merck in 2009. His tenure there culminated in his role as group vice president of diversified products and global market access. In this capacity, he held global P&L responsibility for the company’s $2.5 billion diversified products franchises and was a member of the global management team. As a trained lawyer who practiced for a decade, he also served as legal director for Schering-Plough’s managed care and commercial group from 1998 to 2002. Before joining Schering-Plough, Berkowitz was a health care attorney for the international law firm Proskauer LLP in New York and Washington, D.C. Berkowitz serves on the board of directors of several publicly traded healthcare companies including Lundbeck A/S and Zealand Pharmaceuticals. He also served as the Chairman of privately held PharmaTwoB and as a Board Member of the privately held prescription digital therapeutics company, Click Therapeutics. Berkowitz previously served on the Board of Directors of the Swiss-American Chamber of Commerce, Infinity Pharmaceuticals, Uniphar and Esperion. He has been recognized three times in the Top 100 Most Inspiring in the Life Sciences by PharmaVoice Magazine and serves on the Editorial Advisory Boards of Life Science Leader and Pharmaceutical Commerce magazines.

Meenakshi Datta

Sidley Austin LLP, Partner, Healthcare, Crisis Management and Strategic Response, Privacy and Cybersecurity

Meena Datta is global co-leader of the Sidley’s Healthcare practice and a member of the global Life Sciences team. She manages key strategic matters for life sciences and healthcare companies throughout the world, particularly drug pricing and market access and patient access strategy in the MFN policy landscape. She was a key lawyer on the Sidley team that defeated MFN 1 on behalf of BIO. California Life Scis. Assn. v. CMS, 2020 WL 7696050 (N.D. Cal. 2020). Clients value Meena for her problem-solving and creativity while giving measured guidance to appropriately manage and reduce risk.

Richard Girling

Partner, Centerview Partners

Mr. Girling established the European business of Centerview Partners in London in 2009 and co-founded the Life Sciences practice. The Centerview Partners Healthcare team has advised on a number of significant transactions including: AstraZeneca on the $119bn defence from Pfizer, Walgreens Boots Alliance on the $6.5bn sale of its Alliance Healthcare businesses to AmerisourceBergen, Teva on its TL1A partnership transaction with Sanofi, CSL on its acquisition of Aventis Behring and its acquisition of Novartis’ influenza vaccines business, Hikma on its acquisition of Boehringer Ingelheim’s Roxane Laboratories, Galenica on its $2bn IPO of Galenica Santé and separation of Vifor Pharma, Sanofi on its $1.9bn acquisition of Kadmon and up to $1.1bn sale of Enjaymo to Recordati, Takeda on its acquisition of TiGenix and Arvelle Therapeutics on its $960mm sale to Angelini Pharma. Recently Mr. Girling has advised Zealand Pharma on its up to $5.3bn collaboration and licensing agreement with Roche, EsoBiotec on its up to $1bn sale to AstraZeneca and WBA on its $23.7bn sale to Sycamore Partners. Mr. Girling established Merrill Lynch’s European healthcare practice in 1998, and was Global Co Head of Healthcare investment banking for the last six of those years. Following the acquisition by Bank of America, he was appointed the head of the merged Europe, Middle East and Asia (EMEA) and Asia-Pacific healthcare practices for the combined organization. Mr. Girling joined Merrill Lynch in 1998 from Salomon Brothers, where he worked from 1989 to 1998 and was head of the European Pharmaceutical and Healthcare team. Mr. Girling is an Honorary Fellow of St Anne‘s College, Oxford University and a member of the Executive Advisory Board for the Centre for Personalised Medicine at Oxford University. Mr. Girling holds a B.A. and M.A. degrees in Biochemistry from Oxford University.

Mathai Mammen, M.D., Ph.D.

Chairman, CEO, & President, Parabilis Medicines

Mathai Mammen, M.D., Ph.D., is Chairman, CEO, and President of Parabilis Medicines, a biopharmaceutical company pioneering therapies for previously “undruggable” protein targets for patients with serious diseases. Under Mathai’s leadership, Parabilis has established a differentiated portfolio of potentially transformational medicines targeting disease-driving biology long considered out of reach, including zolucatetide (previously FOG-001), the first and only inhibitor of the elusive β-catenin:TCF interaction, and promising discovery-stage assets targeting ERG and allosteric ARON in prostate cancer – together reflecting the HeliconTM platform’s ability to repeatedly engage high-difficulty targets. Under Mathai’s leadership, Parabilis has established a differentiated portfolio of potentially transformational medicines targeting disease-driving biology long considered out of reach, including zolucatetide (previously FOG-001), the first and only inhibitor of the elusive β-catenin:TCF interaction, and promising discovery-stage assets targeting ERG and allosteric ARON in prostate cancer – together reflecting the Helicon platform’s ability to repeatedly engage high-difficulty targets. Previously, Mathai served as Global Head of R&D and a member of the Executive Committee at Johnson & Johnson. There, he led and evolved one of the world’s largest pharmaceutical R&D organizations and spearheaded the strategic integration of data science and AI across the portfolio. During his tenure, his team secured global approvals for nine medicines including Tremfya™, Darzalex Faspro™, Carvykti™, Tecvayli™, and Spravato™ and achieved an unprecedented 90% success rate in Phase 2 to Phase 3 transitions. He also oversaw 40+ acquisitions and licenses, , including the acquisition of Inlexzo™, along with 350+ strategic partnerships that expanded J&J’s portfolio and capabilities. Before J&J, Mathai was SVP at Merck, contributing to the development of Keytruda™ and the discovery of enlicitide, and earlier co-founded Theravance, Inc., where he led R&D toward five approved therapies including Breo™, Anoro™, and Trelegy™. In total, he has led the discovery/development of 19 approved medicines. He serves on the boards of Sandoz, Xaira, Kelonia, and GBH, and is an advisor to General Atlantic and Foresite Capital. He holds an M.D. from Harvard/MIT (HST) and a Ph.D. from Harvard University.

Mark C. McKenna

Chairman & CEO Mirador Therapeutics, Inc

Mark C. McKenna is the founder, Chairman, and CEO of Mirador Therapeutics, and a renowned biotech entrepreneur, executive, and director known for his exceptional leadership and visionary approach. Mirador is a next-generation precision medicine company focused on developing first-in-class or best-in-class precision medicines for immunology and inflammation. Launched in 2024, Mirador has raised over $650 million plus from leading life sciences investors and is based in San Diego, CA. Prior to Mirador, Mr. McKenna served as Chairman, President, and CEO of Prometheus Biosciences from 2019 until its acquisition by Merck for $10.8 billion in June 2023. Under his leadership, Prometheus raised over $1 billion in private and public financing, was recognized as the top-performing biotech IPO of 2021, and pioneered the first precision therapeutics clinical trial for immune-mediated diseases. This led to its acquisition by Merck, resulting in the largest buyout of company with a pre-Phase 3 asset to date. Prior to Prometheus Mr. McKenna was the President of Salix Pharmaceuticals and a corporate officer at Bausch + Lomb. There, he revitalized the gastroenterology business through strategic acquisitions and product launches, doubling revenue to over $2 billion and significantly enhancing operating margins. He also spent over a decade at Bausch + Lomb, where he was SVP and General Manager of the US Vision Care business. Mr. McKenna began his career at Johnson & Johnson, where he held several positions of increasing responsibility. He currently serves as the Chairman of Apogee Therapeutics, Inc. (Nasdaq: APGE) and is a board member of Spyre Therapeutics, Inc. (Nasdaq: SYRE) and New Amsterdam Pharma (Nasdaq: NAMS). In addition, Mr. McKenna is a Venture Partner at Arch and Senior Advisor to Fairmount Funds. Mr. McKenna holds a B.S. in marketing from Arizona State University and an MBA from Azusa Pacific University. Mr. McKenna also completed the Wharton’s Fellows Program at the University of Pennsylvania School of Business. Mr. McKenna is passionate about solving big problems in medicine and is regularly featured on CNBC’s Mad Money and Bloomberg radio. In addition, Mr. Mckenna is a frequent speaker at the Longwood Healthcare Conference and other industry thought leader events. In 2023 he was selected as EY’s Entrepreneur of the year, being recognized for his contributions to advancement of entrepreneurship and science.

Amit Mehta

Chief Operating Officer & Chief Business Officer, Dren Bio

Amit Mehta joined Dren Bio in October 2023 and currently serves as our COO and CBO. Dr. Mehta most recently served as the VP and Head of Business Development at Genentech. In this role, Dr. Mehta was a core member of the Genentech Research and Early Development (gRED) Leadership Team, Research Review Committee, Early Stage Portfolio Committee and led a high-performing team that helped source and execute several strategic partnerships. During his 18-year tenure at Genentech, Dr. Mehta held roles of increasing responsibility that spanned process development, manufacturing, product strategy and business development. He led multiple teams over the years that made significant contributions to numerous early and late-stage programs, helped shape therapeutic area strategies and established vital external partnerships across technology platforms, personalized healthcare, and several therapeutic areas. Dr. Mehta received his Bachelor of Engineering in Chemical Engineering from Bangalore University and a PhD in Chemical Engineering from Pennsylvania State University.

Dr Moncef Slaoui

Chairman Curevo Vaccine

Dr Moncef Slaoui, a Moroccan Belgian and American scientist, holds a PhD in Immunology. He spent a long career in vaccine and medicine research and development during which he was involved in the development of several vaccines including the first ever vaccine against Malaria. In 2020 he was the Chief Scientific Advisor to Operation Warp Speed. Under his leadership the Operation enabled the fastest ever development manufacturing and approval of COVID19 vaccines.

He was Chairman of R&D at GSK where his career spanned almost 30 years. After retiring from GSK in 2017, he joined Medicxi ventures and since remained a dynamic force in life sciences, serving on the boards of several Biotechnology companies including Moderna and Vaxcyte (2017-2020). He currently chairs the boards of Altesa Arcturus and Curevo.

In 2016, Dr Slaoui was recognized as one of Fortune's 50 Greatest World Leaders for his work in under-researched diseases common in the developing world.

Nenad Tomasevic

Chief Executive Officer & Founder, Dren Bio

Nenad Tomasevic co-founded Dren Bio as CEO in May 2019 and has served on our board of directors since inception. Dr. Tomasevic most recently served as VP of Research for Allakos, a company he helped co-found after identifying the original opportunity for developing therapeutic antibodies against Siglec-8. During his time at Allakos, he was responsible for all research and nonclinical development functions. Prior to co-founding Allakos, Dr. Tomasevic previously held positions at KaloBios and Nuvelo, where his focus was on the development of therapeutic antibodies. Dr. Tomasevic began his career at Cytokinetics after receiving his PhD in protein chemistry from the University of Belgrade and completing his postdoctoral training at the National Institutes of Health (NIDDK, Genetics and Biochemistry Branch) in Bethesda, Maryland.

Stephen J. Ubl

President and Chief Executive Officer, Pharmaceutical Research and Manufacturers of America (PhRMA)

Stephen J. Ubl is president and chief executive officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents America’s leading biopharmaceutical research companies. The U.S. biopharmaceutical sector directly employs more than 800,000 Americans and invests more than $100 billion in research and development annually – more than any other industry in America. Ubl leads PhRMA’s work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery and access to life-saving medicines. Ubl is recognized around the world as a leading health care advocate and policy expert who collaborates successfully with diverse stakeholder groups – including patient and physician groups, regulators, public and private payers, and global trade organizations – to help ensure timely patient access to innovative treatments and cures. The New York Times writes, “If anyone can find areas of agreement with the critics, or at least work productively with them, it may be Mr. Ubl. He is more conversant with the intricacies of health policy, and more adept at the politics." Previously, Ubl served as president and CEO of medical technology association AdvaMed, where he helped facilitate landmark reforms related to the U.S. Food and Drug Administration product review process and Medicare’s coverage and reimbursement of medical technologies. He led the industry’s defense of breakthrough R&D, successfully delaying an innovation-stifling device tax, and, in 2013, was recognized by a leading industry publication as one of 10 people to have a lasting impact on the medical technology industry. Ubl has worked extensively with patient advocacy organizations in health policy, including longstanding service on the board of the National Health Council, a leading umbrella organization for voluntary health care organizations and has been personally involved with JDRF (formerly known as the Juvenile Diabetes Research Foundation). He is routinely recognized as one of Washington’s most effective advocates. Ubl has been recognized on Business Insider’s “DC Healthcare Power Players” and Modern Healthcare’s “100 Most Influential People in Healthcare.” He is identified as a top health influencer by Medical Marketing & Media and PR Week magazines.

CONFERENCE LOCATION

Park Hyatt Zurich

Beethovenstrasse 21, Zürich
8002 Zürich

Park Hyatt Zurich is perfectly situated between the picturesque Lake Zurich and the famous Old Town. Indulge in the finest elements of the Swiss commitment to serenity, luxury and art. Enjoy culinary delights, first-class service and all that Zurich has to offer, right from your doorstep.

MONDAY DINNER

AURA Banquet Hall

Bleicherweg 5, Zürich
8001 Zürich

SUNDAY DINNER

Restaurant Seerose

Seestrasse 493, Zürich
8038 Zürich

REGISTRATION